
## Rocco Haase

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8361425/publications.pdf Version: 2024-02-01



POCCO HAASE

#	Article	IF	CITATIONS
1	Cost of illness in multiple sclerosis by disease characteristics – A review of reviews. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 177-195.	0.7	10
2	Digital Innovation in Multiple Sclerosis Management. Brain Sciences, 2022, 12, 40.	1.1	4
3	Transparent Quality Optimization for Machine Learning-Based Regression in Neurology. Journal of Personalized Medicine, 2022, 12, 908.	1.1	0
4	Fear of falling and falls in people with multiple sclerosis: A literature review. Multiple Sclerosis and Related Disorders, 2021, 47, 102609.	0.9	26
5	Electronic Health Interventions in the Case of Multiple Sclerosis: From Theory to Practice. Brain Sciences, 2021, 11, 180.	1.1	29
6	Digital Twins for Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 669811.	2.2	108
7	Improving Digital Patient Care: Lessons Learned from Patient-Reported and Expert-Reported Experience Measures for the Clinical Practice of Multidimensional Walking Assessment. Brain Sciences, 2021, 11, 786.	1.1	8
8	Profiles of eHealth Adoption in Persons with Multiple Sclerosis and Their Caregivers. Brain Sciences, 2021, 11, 1087.	1.1	10
9	Using Machine Learning Algorithms for Identifying Gait Parameters Suitable to Evaluate Subtle Changes in Gait in People with Multiple Sclerosis. Brain Sciences, 2021, 11, 1049.	1.1	12
10	Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation. Frontiers in Immunology, 2021, 12, 715195.	2.2	1
11	Digital Biomarkers in Multiple Sclerosis. Brain Sciences, 2021, 11, 1519.	1.1	38
12	Automated Analysis of the Two-Minute Walk Test in Clinical Practice Using Accelerometer Data. Brain Sciences, 2021, 11, 1507.	1.1	4
13	Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation. Frontiers in Immunology, 2021, 12, 715195.	2.2	14
14	Tolerability and Efficacy of Clindamycin/Tretinoin versus Adapalene/Benzoyl Peroxide in the Treatment of Acne Vulgaris. Journal of Drugs in Dermatology, 2021, 20, 295-301.	0.4	3
15	Differentiating societal costs of disability worsening in multiple sclerosis. Journal of Neurology, 2020, 267, 1035-1042.	1.8	34
16	Patient―versus physicianâ€reported relapses in multiple sclerosis: insights from a large observational study. European Journal of Neurology, 2020, 27, 2531-2538.	1.7	12
17	The Dresden Protocol for Multidimensional Walking Assessment (DMWA) in Clinical Practice. Frontiers in Neuroscience, 2020, 14, 582046.	1.4	11
18	Gender disparities in health resource utilization in patients with relapsing–remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642096027.	1.5	9

Rocco Haase

#	Article	IF	CITATIONS
19	Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis. Pharmacoeconomics, 2020, 38, 883-892.	1.7	10
20	Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration. Frontiers in Neurology, 2020, 11, 391.	1.1	8
21	Data Collection in Multiple Sclerosis: The MSDS Approach. Frontiers in Neurology, 2020, 11, 445.	1.1	20
22	<p>Health-Related Quality of Life and the Relationship to Treatment Satisfaction in Patients with Multiple Sclerosis: Insights from a Large Observational Study</p> . Patient Preference and Adherence, 2020, Volume 14, 869-880.	0.8	16
23	Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 56.	2.2	20
24	The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study. Journal of Medical Internet Research, 2020, 22, e17921.	2.1	23
25	Review: Patient-reported outcomes in multiple sclerosis care. Multiple Sclerosis and Related Disorders, 2019, 33, 61-66.	0.9	94
26	Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e555.	3.1	87
27	Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231983513.	1.1	9
28	Diagnostischer Wert von klinischen Befunden und Biomarkern als mögliche Risikofaktoren für die diabetische Retinopathie: Ergebnisse einer Kohortenstudie mit optischer Kohäenztomografie (OCT). Diabetologie Und Stoffwechsel, 2019, 14, .	0.0	0
29	Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach. Expert Opinion on Drug Safety, 2018, 17, 369-378.	1.0	32
30	Perceptions on the value of bodily functions in multiple sclerosis. Acta Neurologica Scandinavica, 2018, 137, 356-362.	1.0	71
31	Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up. Frontiers in Neurology, 2018, 9, 1071.	1.1	30
32	Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients. Frontiers in Immunology, 2018, 9, 2669.	2.2	30
33	Sudomotor Testing of Diabetes Polyneuropathy. Frontiers in Neurology, 2018, 9, 803.	1.1	33
34	An Innovative Technique to Assess Spontaneous Baroreflex Sensitivity with Short Data Segments: Multiple Trigonometric Regressive Spectral Analysis. Frontiers in Physiology, 2018, 9, 10.	1.3	8
35	Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?. Multiple Sclerosis Journal, 2018, 24, 1337-1346.	1.4	18
36	Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation. Journal of Neuroinflammation, 2017, 14, 41.	3.1	54

Rocco Haase

#	ARTICLE	IF	CITATIONS
37	Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson's disease. Scientific Reports, 2017, 7, 7012.	1.6	4
38	Autonomic Dysfunction in Wilson's Disease: A Comprehensive Evaluation during a 3-Year Follow Up. Frontiers in Physiology, 2017, 8, 778.	1.3	13
39	Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis. Frontiers in Neuroscience, 2017, 11, 540.	1.4	14
40	Serum and Plasma Levels of Vascular Endothelial Growth Factors in Relation to Quality of Glucose Control, Biomarkers of Inflammation, and Diabetic Nephropathy. Hormone and Metabolic Research, 2016, 48, 529-534.	0.7	27
41	Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey. Therapeutic Advances in Neurological Disorders, 2016, 9, 250-263.	1.5	60
42	Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System. Interactive Journal of Medical Research, 2016, 5, e2.	0.6	44
43	Colonization and Infection due to Multi-resistant Bacteria in Neonates: A Single Center Analysis. Klinische Padiatrie, 2014, 226, 8-12.	0.2	11
44	Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients – an observational study. Experimental & Translational Stroke Medicine, 2013, 5, 7.	3.2	13
45	Modern communication technology skills of patients with multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1240-1241.	1.4	28
46	Remediation of mould damaged building materials—efficiency of a broad spectrum of treatments. Journal of Environmental Monitoring, 2012, 14, 908.	2.1	14
47	Use and Acceptance of Electronic Communication by Patients With Multiple Sclerosis: A Multicenter Questionnaire Study. Journal of Medical Internet Research, 2012, 14, e135.	2.1	75
48	Bevacizumab-induced changes in small arterial dilatation measured in vivo by dynamic retinal vessel analysis Journal of Clinical Oncology, 2010, 28, 3575-3575.	0.8	0